Intravenous immunoglobulin (IVIg) therapy
Today, most Ig therapy patients in the United States receive their treatment
intravenously (or through the vein). For more than 20 years, IVIg
infusions have been proven safe and effective for thousands of patients
worldwide.
Intravenous immunoglobulin is often administered once every three or four
weeks. Typically, a nurse in a hospital, infusion center, physician’s office, or
in the patient's home administers therapy. For patients treated at home,
arrangements must be made to have a nurse present to provide treatment. IV
infusions require a pole holding a bag of medication, a needle that's inserted
into a vein in the arm, and an infusion pump that controls how much and how fast
the medication is delivered.
For more information on ZLB Behring's intravenous immunoglobulin product,
please click on the link below.
Carimune® NF
Immune Globulin
Intravenous (Human)
Warning: Immune Globulin Intravenous (Human) (IGIV) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. See boxed warning and the PRECAUTIONS and DOSAGE AND ADMINISTRATION section of
Full Prescribing Information for Carimune® NF Nanofiltered
for important information intended to reduce the risk of acute renal failure.